Can Letrozole Cause Diarrhea and Other Side Effects?

Letrozole can cause diarrhea, though it is not one of the drug’s most frequently reported side effects. In a study of women with polycystic ovarian syndrome taking letrozole, about 10% experienced gastrointestinal symptoms including nausea, vomiting, diarrhea, and abdominal discomfort, and the distress was transient in all cases.¹ The more prominent side effects of letrozole involve the joints and bones, and these tend to demand more attention from people taking the drug long-term. Understanding the full range of what letrozole can do to your body helps you separate the temporary annoyances from the effects that genuinely warrant a conversation with your oncologist.

Why Letrozole Causes Side Effects in the First Place

Letrozole belongs to a class of drugs called aromatase inhibitors. Aromatase is the enzyme responsible for the final step in producing estrogen, and letrozole blocks it with extraordinary potency, achieving near-complete suppression of estrogen in peripheral tissues.² That is exactly what you want if you have a hormone-receptor-positive breast cancer that feeds on estrogen. But estrogen does a lot of other work in the body: it protects bones, lubricates joints, helps regulate cholesterol, and plays a role in how the gastrointestinal lining manages fluid balance. Strip estrogen away and those systems feel the absence.

The gastrointestinal tract has estrogen receptors that help modulate ion secretion and the protective lining of the gut. Research has shown that estrogen and its receptors influence how the gut epithelium handles bicarbonate and chloride secretion, processes tied to fluid balance and mucosal protection.³ When letrozole drives estrogen to near-undetectable levels, these gut processes can be disrupted, which may explain why some people develop diarrhea, bloating, or nausea. The good news is that for most people, these GI symptoms are mild, short-lived, and do not require stopping the drug.

The Side Effects You Are More Likely to Notice

If you have just started letrozole or are about to, diarrhea probably should not be your chief worry. The side effects that affect quality of life most frequently are musculoskeletal: joint pain, stiffness, and reduced grip strength. These symptoms, sometimes grouped under the term aromatase inhibitor-associated musculoskeletal syndrome, affect up to half of all women on aromatase inhibitor therapy.⁴

The typical pattern is symmetrical joint pain, most often in the wrists, hands, and knees, with pronounced morning stiffness that eases as you move through the day. Symptoms usually appear within the first couple of months, with a median onset around six weeks, and tend to peak at about six months.⁵ Some women develop carpal tunnel syndrome or trigger finger. Imaging studies of affected patients have found thickening and fluid accumulation in the tendon sheaths surrounding the digital flexor tendons, which helps explain the stiffness and the difficulty making a fist in the morning.⁶

These symptoms are not just an inconvenience. In one study, six patients had to stop treatment entirely because the joint problems were too severe to tolerate.⁶ Across all aromatase inhibitor users, side effects are a leading reason women stop their medication early, which is a real problem when the drug is reducing their cancer recurrence risk.

What Letrozole Does to Your Bones

Estrogen is one of the body’s main signals to maintain bone density. When aromatase inhibitors push estrogen levels to near-undetectable concentrations in postmenopausal women, bone loss accelerates and fracture risk rises.⁷ In a companion study to a large clinical trial, women who took letrozole after completing five years of tamoxifen experienced a modest but measurable reduction in bone mineral density at the spine and hip compared with women taking a placebo.⁸

The BIG 1-98 study, which compared letrozole and tamoxifen head-to-head and in sequences, confirmed that all aromatase inhibitor regimens reduced bone density. Interestingly, using letrozole for part of the time and tamoxifen for the rest did not spare the bones: the sequential schedules were just as detrimental as letrozole alone.⁹ This is why oncologists typically recommend baseline bone density scans before starting an aromatase inhibitor and periodic follow-up scans during treatment. For women already at elevated fracture risk, bisphosphonates or other bone-protective medications may be added alongside letrozole.

Cholesterol and Cardiovascular Concerns

One of the less publicized effects of letrozole involves lipid levels. In postmenopausal women with breast cancer, letrozole treatment has been associated with increases in total cholesterol, LDL cholesterol, and unfavorable shifts in atherogenic risk ratios.¹⁰ Estrogen generally has a favorable influence on the lipid profile, so suppressing it to near-zero can push cholesterol numbers in the wrong direction.

That said, the clinical significance of these changes is debated. A larger companion lipid study from the MA.17 trial found only marginally significant differences between letrozole and placebo groups at individual time points, with no consistent pattern of worsening across all lipid measures and no meaningful difference in the number of patients exceeding clinical thresholds for concerning lipid levels.¹¹ The practical takeaway is that lipid changes tend to be modest for most women, but if you already have cardiovascular risk factors, it is worth having your cholesterol monitored while on letrozole.

Brain Fog and Cognitive Effects

Many women on aromatase inhibitors report trouble concentrating, memory lapses, or a general mental fuzziness that they sometimes call “chemo brain” even when they never received chemotherapy. Animal research provides a plausible biological basis for these concerns: in both male and female rats, letrozole caused dose-dependent cognitive impairment by blocking estrogen production in the brain itself.¹²

Human evidence is more reassuring, at least from the formal testing that has been done. In the BIG 1-98 randomized trial, self-reported cognitive function, fatigue, psychological distress, and quality of life did not differ significantly between patients taking letrozole and those taking tamoxifen.¹³ This does not necessarily mean letrozole has zero cognitive impact; it may mean both drugs cause similar levels of subtle impairment compared with taking nothing. But if you are choosing between letrozole and tamoxifen specifically, the existing data suggest neither is clearly worse on this front.

Rare but Serious Reactions

Letrozole can cause mild elevations in liver enzymes in up to about 1% of women, but these bumps are generally asymptomatic and resolve on their own without needing to adjust the dose. Severe liver injury from letrozole is genuinely rare. As of a 2017 review, there had been no published cases of clinically apparent liver damage, jaundice, acute liver failure, or chronic hepatitis attributed to long-term letrozole use. The first reported case of drug-induced autoimmune hepatitis linked to letrozole appeared as a single case report.¹⁴ This is reassuring overall, but it does mean that unexplained fatigue, dark urine, or yellowing of the skin while on letrozole should prompt a call to your doctor rather than be brushed off as just another side effect.

How Letrozole Compares to Other Aromatase Inhibitors

There are three aromatase inhibitors in wide use for breast cancer: letrozole, anastrozole, and exemestane. All three share the core mechanism of estrogen suppression, so they also share the same general side-effect profile, but the emphasis differs somewhat. An analysis of spontaneous adverse event reports submitted to the FDA’s reporting system found that all three triggered trigger finger as their strongest signal. The most frequently reported adverse event for letrozole was neutropenia (low white blood cells), while for anastrozole and exemestane it was joint pain.¹⁵

In terms of effectiveness, the differences are small. A large observational study found that five-year disease-free survival was nearly identical for all three drugs, hovering around 87 to 89 percent. At eight years, exemestane fell slightly behind letrozole and anastrozole, with a roughly two-percentage-point difference in disease-free survival. Women starting exemestane were also somewhat more likely to discontinue treatment within five years (about 39%) compared with those on letrozole or anastrozole (about 35% for each).¹⁶ If side effects on one aromatase inhibitor become intolerable, switching to another is a reasonable strategy, since individual responses vary and you might tolerate a different one better.

Why So Many Women Stop Early

Letrozole is typically prescribed for five or more years of adjuvant therapy, which is a long time to live with chronic side effects. The cumulative burden matters: joint pain that is manageable in month three can become unbearable by year two, especially when it stacks with fatigue, mood changes, and sleep disruption. In the IDEAL trial, overall non-compliance after two and a half years of extended adjuvant endocrine therapy was about 18%, and the vast majority of those who stopped, roughly 85%, did so because of side-effect toxicity rather than personal choice unrelated to how the drug made them feel.¹⁷

An integrative review of studies on long-term adherence found that many women felt they lacked adequate understanding of what to expect or practical strategies for managing what they were experiencing. That gap between what patients felt and what their care teams communicated led directly to worse quality of life and premature discontinuation.¹⁸ If you are struggling with letrozole’s side effects, the evidence strongly suggests that bringing those complaints to your oncologist rather than silently stopping the medication leads to better outcomes. Dose adjustments, temporary drug holidays, switching to a different aromatase inhibitor, or adding supportive medications are all options that keep the cancer-fighting benefit while making day-to-day life more tolerable.

Does Exercise Help With the Joint Pain?

You will often hear that exercise can ease aromatase inhibitor-related joint symptoms, and that advice is well-intentioned. A Cochrane systematic review, however, found that the evidence is weak. For preventing musculoskeletal symptoms, the single available study showed no difference in pain scores, grip strength, or medication compliance between exercise and control groups. For managing existing symptoms, the pooled data from four studies covering nearly 300 women showed very uncertain evidence of any effect on worst pain scores, and exercise appeared to make little to no difference in stiffness.¹⁹

This does not mean exercise is pointless. Physical activity has well-established benefits for bone density, cardiovascular health, fatigue, and mood, all of which are relevant when you are on a drug that works against those systems. The honest answer is just that we cannot yet say exercise specifically fixes aromatase inhibitor joint pain based on current trial data. If moving makes you feel better, keep doing it. If someone tells you that exercise alone should be enough to manage your symptoms, that claim goes beyond what the research supports.

Letrozole Beyond Breast Cancer

Letrozole is increasingly used off-label in reproductive medicine, particularly for ovulation induction in women with polycystic ovarian syndrome or unexplained infertility. Compared with clomiphene citrate, the older standard, letrozole has been associated with higher ovulation and live birth rates, a lower risk of multiple pregnancies, and a more favorable effect on the uterine lining.²⁰ In this context, letrozole is used at lower doses and for much shorter durations than in cancer treatment, typically only five days per menstrual cycle. The side-effect experience is consequently milder: the GI symptoms noted earlier (nausea, diarrhea, bloating) were the most common complaints, and none of the women in that study needed to stop the drug.¹

If you are taking letrozole for fertility rather than cancer, the long-term musculoskeletal, bone, and cardiovascular effects discussed above are largely irrelevant to your situation. Your exposure to the drug is measured in days rather than years, and the estrogen suppression reverses quickly once you stop.

Why Side Effects Vary So Much Between Individuals

One of the frustrating things about letrozole is the sheer range of individual responses. Some women sail through five years with nothing more than mild hot flashes, while others are barely functional within months. Part of this variation appears to be genetic. Research into pharmacogenomics has identified variants in genes like CYP19A1 (the gene for aromatase itself), CYP2A6, and the estrogen receptor genes ESR1 and ESR2 that influence how quickly the body metabolizes letrozole and how vulnerable a person’s bones are to estrogen deprivation.²¹ In theory, this information could one day allow oncologists to predict who will tolerate letrozole well and who might do better starting on a different drug. In practice, pharmacogenomic testing for aromatase inhibitor selection is still more research than routine, though it is moving in that direction.

Body weight, age, prior hormone replacement therapy use, smoking status, and whether or not a woman has undergone a hysterectomy also correlate with how much bone density is affected, hinting at a broader web of factors that shape each person’s experience.⁹ Until personalized prescribing catches up with the science, the most practical approach is monitoring: regular bone density scans, lipid panels, and honest reporting of how you feel to a care team that takes those reports seriously.